Manju T. Beier, PharmD
Clinical Associate Professor
University of Michigan College of Pharmacy
Geriatric Consultant Resources LLC
Ann Arbor, Michigan
Jeffrey L. Cummings, MD
Augustus S. Rose Professor of Neurology
Professor of Psychiatry and Biobehavioral Sciences
Director, UCLA Alzheimer's Disease Center
David Geffen School of Medicine at UCLA
Los Angeles, California
Pharmacists & Physicians: 1
Nurses & NPs: 1.2 (50 min. hour)
This program was originally presented as a live audioconference series in April and May of 2006. If you received CME or CE credit for the audioconference, you are not eligible to receive credit through this online program.
Alzheimer’s disease (AD) is the most common form of dementia in the United States. It is estimated that 4.5 million Americans have AD. The greatest risk factor for AD is increasing age—10% of those over 65 and nearly half of all nursing home residents are affected. Over the next 50 years, the prevalence and incidence of AD is expected to increase by four-fold, causing a tremendous caregiver and financial burden. The Alzheimer’s Association and National Institute on Aging estimate that current direct and indirect costs associated with the disease exceed $100 billion annually. By the time baby boomers turn 65, the economic and social impact of AD could exceed the resources necessary to care for them. Slowing the progression of the disease can reduce this burden. While there is a lot of interest in the use of ginkgo biloba, estrogen, non-steroidals and statins, there is insufficient evidence to recommend their use. However, there is good evidence that cholinesterase inhibitors and the N-methyl-D-aspartate (NMDA) receptor antagonist are effective in delaying the progression of the disease thereby deferring the inevitable decline in cognition and function and preventing the emergence of neuropsychiatric symptoms. Clinicians should be prepared to provide evidence-based treatment for AD.
Using a case-based approach, this online activity will review the assessment, diagnosis, and appropriate treatments for AD in the skilled nursing facility resident. Program Developer/Facilitator
. Target Audience
This program has been developed specifically for healthcare professionals caring for Alzheimer’s patients in skilled nursing facilities.
Upon completion of this educational activity, the participant should be able to:
Discuss the prevalence, cost, and burden of illness associated with Alzheimer’s disease (AD).
Cite the screening and diagnostic criteria for AD among elderly long-term care residents.
Identify appropriate individualized therapeutic strategies for residents in skilled nursing facilities.
Assess the current treatment concepts and pharmacologic issues, including efficacy, safety, dosing and combination therapy across the various stages of AD.
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by AKH prior to accreditation of the activity.
Jeffrey Cummings, MD discloses that he is a member of speakers bureaus for Pfizer Inc, Forest Laboratories, Inc., Novartis Pharmaceuticals Corporation and Janssen Pharmaceutica Inc., and on advisory committees for Pfizer Inc, Forest Laboratories, Inc., Novartis Pharmaceuticals Corporation.
Manju T. Beier PharmD discloses that she is a member of speakers bureaus for Forest Laboratories, Inc. and Ortho McNeil Pharmaceutical, and advisory committees for Pfizer Inc, Forest Laboratories, Inc., Ortho McNeil Pharmaceutical, and Eisai.
This educational activity may contain discussion of published and/or investigational uses of pharmaceutical agents. Some uses of these agents may not have been approved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Credit Statements
This activity has been planned and implemented in accordance with the Essential Areas and polices of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH Inc. and Medical Communications Media, Inc. AKH Inc. is accredited by the ACCME to provide continuing medical education for physicians.
AKH Inc. designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
ASCP is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program is accredited for 1.0 contact hour (0.1 CEUs) of continuing education credit. Universal program number 203-999-06-033-H01.
NADONA/LTC is an approved provider of continuing nursing education by the Georgia Nurses Association, an accredited approver by the American Nurses Credentialing Centers Commission on Accreditation # 1087. This program has been approved for 1.2 contact hours by NADONA/LTC. (Credit is based on a 50-minute hour.)
AKH Inc. is approved as a provider of nurse practitioner continuing education by the American Academy of Nurse Practitioners. Provider #030803. AKH Inc. designates this educational activity for 1.2 contact hour(s). (Credit is based on a 50-minute hour.)
Participants must successfully complete the post-test (70% or higher) and submit an evaluation to receive credit. Commercial Support Statements
Supported by an educational grant from Eisai & Pfizer Neuroscience.
Please turn off all pop-up blockers to assure access to the educational activity.
Click on the "Start program" icon. If you are not already logged in to the site, this will bring you to the login/registration page where you will be able to register as a new cmecorner.com member or check existing registration information. When ready, click on the "Continue to Program" icon at the bottom of the screen.
The next main menu screen will permit you to check for or download the Flash player required to run this program. Clicking on "slides" on this screen will begin the program presentation. You may return to this main menu to view the question and answer segment, the reference list, and the CME/CE post-test and evaluation. The program will take approximately 60 minutes to complete.
Upon completion of the program, click on the post-test button to register and access the post-test and program evaluation.
Instructions for completing and submitting the post-test are provided on the post-test screen. A minimum score of 70% on the post-test is required for a CME/CPE certificate/statement.
None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this activity are those of the speakers and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, AKH Inc., the American Society of Consultant Pharmacists, the National Association of Directors of Nursing Administration in Long-Term Care, Eisai, or Pfizer Neuroscience. Any medications or other diagnostic or treatment procedures discussed by the program speakers should not be utilized by clinicians without evaluation of their patients’ conditions and possible contraindications or risks, and without a review of any applicable manufacturer’s product information and comparison with the recommendations of other authorities.